Latest Nasdaq News

Betashares’ 2026 annual report shows a sharp split across its thematic ETF range, led by a $1.886 billion accounting profit for the Nasdaq 100 ETF and a $97.7 million loss for its Australian technology fund. The report also flags a 24.89% post-year-end fall in the Space Industry ETF’s NAV and a name change for the energy-transition strategy.

Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.

Mesoblast has secured FDA approval to add a new potency assay to commercial release and stability testing for Ryoncil, its approved cell therapy for paediatric graft-versus-host disease. The regulatory decision supports tighter monitoring as manufacturing processes evolve, but the company disclosed no direct financial impact or clinical outcome data.

Reach Resources has increased the Blue Heaven resource by 30% to 80,000 ounces while advancing a proposed profit-sharing mining arrangement with Andel Resources. The progress came alongside a sharply larger FY2026 loss and a balance sheet still dependent on future project execution.

European Lithium has dispatched the scheme booklet for its proposed merger with NASDAQ-listed Critical Metals Corp., putting shareholders and optionholders on the path to votes on 22 October. The transaction remains conditional on securityholder, Court and regulatory approvals, with implementation targeted for 5 November.

Jindalee Lithium has filed a third amended US registration statement after a second round of SEC comments, keeping its proposed US Elemental Nasdaq listing targeted for the fourth quarter. The transaction still depends on SEC effectiveness, shareholder approval, Nasdaq clearance, funding and other closing conditions.

Telix will acquire ITM in a proposed US$1.65 billion deal that combines a commercial radioisotope supplier with Telix’s precision medicine and therapeutic pipeline. The transaction could give Telix greater supply-chain control and entry into a validated cancer treatment market, but it also brings dilution, integration risk and an unresolved FDA pathway for ITM-11.

IperionX says its GenX continuous titanium furnace processed more than 500 kilograms of powder while using substantially less power, magnesium and hydrogen than batch HAMR production. The results strengthen the case for an industrial-scale line, although further optimisation and engineering work are still required.

European Lithium’s proposed takeover by Critical Metals Corp. can now proceed to shareholder votes, but an independent expert has warned that the share scheme is not fair, even while calling it reasonable and in shareholders’ best interests absent a superior proposal. The decisive votes are scheduled for 22 October 2026.

Resolution Minerals has reported its strongest gold grades to date at Golden Gate South, including 1 metre at 14.8 g/t gold, while extending the identified mineralised zone to approximately 600 metres. The results point to possible higher-grade feeder zones, but true widths and the broader continuity of the system remain unconfirmed.

Jindalee Lithium is moving crews onto its McDermitt project in Oregon, with Phase 1 drilling of up to 100 sites scheduled to begin in late September. Its proposed US Elemental Nasdaq listing remains targeted for the fourth quarter, although the planned US$20 million to US$30 million PIPE financing is not yet binding.

JPMorgan US 100Q Equity Premium Income ETF (ASX:JPH) lifted operating profit to A$15.678 million for the year ended 30 June 2026, while net assets rose to A$106.991 million. The fund is also preparing to move its underlying exposure from a Nasdaq-listed ETF to an Irish UCITS vehicle traded in London, with total management fees and costs unchanged at 0.40% a year.